Medical - Devices
Compare Stocks
5 / 10Stock Comparison
PROF vs EDAP vs ISRG vs AEYE vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Software - Application
Medical - Devices
PROF vs EDAP vs ISRG vs AEYE vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Software - Application | Medical - Devices |
| Market Cap | $217M | $156M | $161.07B | $100M | $99.94B |
| Revenue (TTM) | $14M | $70M | $10.58B | $40M | $35.48B |
| Net Income (TTM) | $-25M | $-13M | $2.98B | $-3M | $4.61B |
| Gross Margin | 69.1% | 46.8% | 66.3% | 78.3% | 61.9% |
| Operating Margin | -287.4% | -38.2% | 30.5% | -7.9% | 17.9% |
| Forward P/E | 5.1x | — | 43.3x | — | 14.1x |
| Total Debt | $6M | $28M | $303M | $721K | $28.52B |
| Cash & Equiv. | $82M | $17M | $3.37B | $5M | $2.22B |
PROF vs EDAP vs ISRG vs AEYE vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Profound Medical Co… (PROF) | 100 | 55.5 | -44.5% |
| Edap Tms S.a. (EDAP) | 100 | 153.0 | +53.0% |
| Intuitive Surgical,… (ISRG) | 100 | 232.8 | +132.8% |
| AudioEye, Inc. (AEYE) | 100 | 92.8 | -7.2% |
| Medtronic plc (MDT) | 100 | 77.2 | -22.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PROF vs EDAP vs ISRG vs AEYE vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PROF is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 61.1%, EPS growth 231.8%, 3Y rev CAGR 34.8%
- 61.1% revenue growth vs MDT's 3.6%
- Better valuation composite
EDAP ranks third and is worth considering specifically for momentum.
- +80.9% vs AEYE's -27.9%
ISRG is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 5.5% 10Y total return vs MDT's 26.5%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- PEG 1.99 vs MDT's 36.00
- 28.2% margin vs PROF's -184.2%
Among these 5 stocks, AEYE doesn't own a clear edge in any measured category.
MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Beta 0.47 vs AEYE's 2.29
- 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 61.1% revenue growth vs MDT's 3.6% | |
| Value | Better valuation composite | |
| Quality / Margins | 28.2% margin vs PROF's -184.2% | |
| Stability / Safety | Beta 0.47 vs AEYE's 2.29 | |
| Dividends | 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +80.9% vs AEYE's -27.9% | |
| Efficiency (ROA) | 175.8% ROA vs PROF's -27.8%, ROIC 6.0% vs -239.6% |
PROF vs EDAP vs ISRG vs AEYE vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PROF vs EDAP vs ISRG vs AEYE vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
MDT leads 2 • PROF leads 0 • EDAP leads 0 • AEYE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 2626.5x PROF's $14M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to PROF's -184.2%. On growth, EDAP holds the edge at +31.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $14M | $70M | $10.6B | $40M | $35.5B |
| EBITDAEarnings before interest/tax | -$38M | -$24M | $3.8B | -$504,000 | $9.4B |
| Net IncomeAfter-tax profit | -$25M | -$13M | $3.0B | -$3M | $4.6B |
| Free Cash FlowCash after capex | -$39M | -$17M | $2.8B | $2M | $5.4B |
| Gross MarginGross profit ÷ Revenue | +69.1% | +46.8% | +66.3% | +78.3% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -2.9% | -38.2% | +30.5% | -7.9% | +17.9% |
| Net MarginNet income ÷ Revenue | -184.2% | -18.9% | +28.2% | -7.6% | +13.0% |
| FCF MarginFCF ÷ Revenue | -2.9% | -25.1% | +26.8% | +5.5% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +31.4% | +23.0% | +7.9% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +152.8% | +2.3% | +18.8% | +29.0% | -11.9% |
Valuation Metrics
MDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 5.1x trailing earnings, PROF trades at a 91% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), ISRG offers better value at 2.65x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $217M | $156M | $161.1B | $100M | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $141M | $166M | $158.0B | $96M | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | 5.08x | -5.33x | 57.62x | -32.36x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 43.35x | — | 14.13x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.65x | — | 36.00x |
| EV / EBITDAEnterprise value multiple | — | — | 43.62x | — | 14.32x |
| Price / SalesMarket cap ÷ Revenue | 13.23x | 2.20x | 16.00x | 2.49x | 2.98x |
| Price / BookPrice ÷ Book value/share | 2.38x | 8.02x | 9.17x | 20.91x | 2.08x |
| Price / FCFMarket cap ÷ FCF | — | — | 64.67x | — | 19.28x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-65 for EDAP. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to EDAP's 1.43x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs EDAP's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -44.9% | -65.4% | +16.9% | -47.8% | +9.4% |
| ROA (TTM)Return on assets | -27.8% | -18.8% | +14.8% | -9.5% | +175.8% |
| ROICReturn on invested capital | -2.4% | -69.2% | +15.0% | -42.4% | +6.0% |
| ROCEReturn on capital employed | -33.8% | -56.0% | +16.5% | -17.7% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.07x | 1.43x | 0.02x | 0.15x | 0.59x |
| Net DebtTotal debt minus cash | -$75M | $10M | -$3.1B | -$5M | $26.3B |
| Cash & Equiv.Liquid assets | $82M | $17M | $3.4B | $5M | $2.2B |
| Total DebtShort + long-term debt | $6M | $28M | $303M | $721,000 | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | — | -16.21x | — | -2.79x | 9.08x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $3,546 for PROF. Over the past 12 months, EDAP leads with a +80.9% total return vs AEYE's -27.9%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs EDAP's -28.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.5% | +22.4% | -19.3% | -18.7% | -18.1% |
| 1-Year ReturnPast 12 months | +48.9% | +80.9% | -15.4% | -27.9% | -2.8% |
| 3-Year ReturnCumulative with dividends | -47.9% | -63.3% | +49.6% | +20.6% | -4.2% |
| 5-Year ReturnCumulative with dividends | -64.5% | -37.8% | +58.7% | -60.2% | -27.7% |
| 10-Year ReturnCumulative with dividends | -26.3% | +18.9% | +554.2% | +102.2% | +26.5% |
| CAGR (3Y)Annualised 3-year return | -19.5% | -28.4% | +14.4% | +6.4% | -1.4% |
Risk & Volatility
Evenly matched — EDAP and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EDAP currently trades 82.4% from its 52-week high vs AEYE's 49.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.52x | 0.74x | 1.00x | 2.18x | 0.42x |
| 52-Week HighHighest price in past year | $8.95 | $5.05 | $603.88 | $16.39 | $106.33 |
| 52-Week LowLowest price in past year | $3.76 | $1.21 | $427.84 | $5.31 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +80.0% | +82.4% | +75.1% | +49.4% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 60.1 | 54.8 | 42.4 | 61.3 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 212K | 38K | 1.8M | 194K | 7.8M |
Analyst Outlook
MDT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: PROF as "Buy", EDAP as "Buy", ISRG as "Buy", MDT as "Buy". Consensus price targets imply 67.6% upside for PROF (target: $12) vs 37.3% for ISRG (target: $623). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | — | Buy |
| Price TargetConsensus 12-month target | $12.00 | $6.00 | $622.60 | — | $109.50 |
| # AnalystsCovering analysts | 7 | 8 | 55 | — | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.6% |
| Dividend StreakConsecutive years of raises | — | — | — | 1 | 36 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | 0.0% | +3.2% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
PROF vs EDAP vs ISRG vs AEYE vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PROF or EDAP or ISRG or AEYE or MDT a better buy right now?
For growth investors, Profound Medical Corp.
(PROF) is the stronger pick with 61. 1% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Profound Medical Corp. (PROF) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate Profound Medical Corp. (PROF) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PROF or EDAP or ISRG or AEYE or MDT?
On trailing P/E, Profound Medical Corp.
(PROF) is the cheapest at 5. 1x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 1. 99x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — PROF or EDAP or ISRG or AEYE or MDT?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -64. 5% for Profound Medical Corp. (PROF). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus PROF's -29. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PROF or EDAP or ISRG or AEYE or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
42β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 414% more volatile than MDT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 143% for Edap Tms S. a. — giving it more financial flexibility in a downturn.
05Which is growing faster — PROF or EDAP or ISRG or AEYE or MDT?
By revenue growth (latest reported year), Profound Medical Corp.
(PROF) is pulling ahead at 61. 1% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Profound Medical Corp. grew EPS 231. 8% year-over-year, compared to -52. 9% for Edap Tms S. a.. Over a 3-year CAGR, PROF leads at 34. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PROF or EDAP or ISRG or AEYE or MDT?
Profound Medical Corp.
(PROF) is the more profitable company, earning 258. 4% net margin versus -41. 5% for Edap Tms S. a. — meaning it keeps 258. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -256. 3% for PROF. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PROF or EDAP or ISRG or AEYE or MDT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 1. 99x versus Medtronic plc's 36. 00x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 29. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PROF: 67. 6% to $12. 00.
08Which pays a better dividend — PROF or EDAP or ISRG or AEYE or MDT?
In this comparison, MDT (3.
6% yield) pays a dividend. PROF, EDAP, ISRG, AEYE do not pay a meaningful dividend and should not be held primarily for income.
09Is PROF or EDAP or ISRG or AEYE or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
42), 3. 6% yield). AudioEye, Inc. (AEYE) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, AEYE: +96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PROF and EDAP and ISRG and AEYE and MDT?
These companies operate in different sectors (PROF (Healthcare) and EDAP (Healthcare) and ISRG (Healthcare) and AEYE (Technology) and MDT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: PROF is a small-cap high-growth stock; EDAP is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; AEYE is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while PROF, EDAP, ISRG, AEYE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.